Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 8/20 | 0.43 |
| ▸ | TYK2 | P29597 | 4/20 | 0.43 |
| ▸ | JAK3 | P52333 | 7/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | BCL6 | P41182 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923264 | 0.86 | JAK1 (0.36) | JAK1TYK2JAK3JAK2MEN1 | |
| SCHEMBL9923050 | 0.86 | JAK1 (0.36) | JAK1TYK2JAK3JAK2MEN1 | |
| SCHEMBL9923304 | 0.86 | JAK1 (0.36) | JAK1TYK2JAK3JAK2MEN1 | |
| SCHEMBL1160522 | 0.80 | L3MBTL1 (0.46) | JAK1TYK2JAK3JAK2MEN1 | |
| SCHEMBL9923091 | 0.78 | JAK1 (0.67) | JAK1TYK2JAK3JAK2 | |
| SCHEMBL9923089 | 0.76 | MAP2K1 (0.46) | CSNK2A1 | |
| SCHEMBL9923334 | 0.76 | JAK1 (0.42) | JAK1TYK2JAK3JAK2MEN1 | |
| SCHEMBL1160281 | 0.75 | JAK1 (0.64) | JAK1TYK2JAK3JAK2CDK2 | |
| SCHEMBL1160492 | 0.74 | JAK1 (0.63) | JAK1TYK2JAK3JAK2CDK2 | |
| SCHEMBL1160503 | 0.74 | JAK1 (0.63) | JAK1TYK2JAK3JAK2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | JAK1 1/4885TYK2 10/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.